Distinct kinetic features of innate and adaptive responses in influenza A versus influenza B–infected mice
The Journal of Immunology · 2026
DOI: 10.1093/jimmun/vkag196 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2026. Verfasst von Sean A Nelson und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY, United States. Hauptthemen laut MEDLINE: Immunity, Innate, Adaptive Immunity, Orthomyxoviridae Infections, Influenza A virus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, NIAID Collaborative Influenza Vaccine Innovation Centers, and National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Influenza B infection is an important source of morbidity and mortality, especially in vulnerable populations such as children. Improved vaccines and antiviral therapeutics are hindered by gaps in knowledge about influenza B viruses (IBVs). We examined the immune responses in the lung, at the kinetic interface between the innate and adaptive response with a focus on the CD4 T-cell response to infection. Using a mouse model of infection with influenza A virus (IAV) A/California/04/2009 and influenza B virus (IBV) B/Brisbane/60/2008, striking differences in early cytokines and chemokines associated with induction of Th1-biased immune responses were identified. Quantifying these mediators on a temporal basis, IBV infection leads to earlier lung expression of the cytokines IFN-γ, IP-10, and MIP1-B in the lung relative to IAV. Given the critical role for IFN-γ in antiviral responses, the use of direct ex vivo cytokine staining and multiparameter flow cytometry revealed that, at day 6 after infection, when lung lysates contained the highest levels of IFN-γ, significant differences were found in the abundance of IFN-γ–producing Ly6C+ monocytes, CD4 T cells, and CD8 T cells in the IBV–infected lung, but not the IAV-infected lung. Data from a reporter mouse model of T-cell receptor engagement, epitope-specific cytokine enzyme-linked immunospot assays, quantitative lung cytokine abundance, and earlier viral clearance suggest a distinctive mechanism of IBV and IAV responses whereby the kinetics in recruitment of epitope-specific T cells to the IBV-infected lung is driven by early innate responses and leads to more rapid viral clearance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY, United States.
- Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, United States.
- Center for Influenza Disease and Emergence Response, University of Rochester Medical Center, Rochester, NY, United States.
ORCID-Profile: Andrea J Sant
Förderung
- NHLBI NIH HHS
- NIAID Collaborative Influenza Vaccine Innovation Centers, and National Heart, Lung, and Blood Institute
Zitieren
APA
Nelson, S. A., Rattan, A., Marathe, B., White, C. L., Eismann, M. C., Richards, K. A., Webby, R. J., & Sant, A. J. (2026). Distinct kinetic features of innate and adaptive responses in influenza A versus influenza B–infected mice. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkag196
Vancouver
Nelson SA, Rattan A, Marathe B, White CL, Eismann MC, Richards KA, et al. Distinct kinetic features of innate and adaptive responses in influenza A versus influenza B–infected mice. The Journal of Immunology. 2026. doi:10.1093/jimmun/vkag196
BibTeX
@article{Nelson2026,
author = {Nelson, Sean A and Rattan, Ajitanuj and Marathe, Bindumadhav and White, Chantelle L and Eismann, Max C and Richards, Katherine A and Webby, Richard J and Sant, Andrea J},
title = {Distinct kinetic features of innate and adaptive responses in influenza A versus influenza B–infected mice},
journal = {The Journal of Immunology},
year = {2026},
doi = {10.1093/jimmun/vkag196}
}
EUVIMED